logo-loader

SkinBioTherapeutics safety data out on first human studies

Published: 09:50 12 Nov 2018 GMT

SkinBioTherapeutics' (LON:SBTX) Dr. Catherine O'Neill tells Proactive Investors London about an important milestone for the company's skin irritancy product, as the results from their first human studies are announced. O'Neill says the team is 'very pleased' with the data which allows them now to scale up their technology to a cream and take it to manufacturing.

These initial results are effectively a precursor to the main element of the study involving 120 volunteers with dry skin. This kicks off later in November and will assess the longer-term moisturisation potential of the technology.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

38 minutes ago